By David Bautz, PhD NASDAQ:BVXV READ THE FULL BVXV RESEARCH REPORT Business Update Second Cohort of Phase 3 Trial Fully Enrolled On November 18, 2019, BiondVax Pharmaceuticals, Ltd. (NASDAQ:BVXV) announced that the second cohort of the Phase 3 trial of the company’s universal influenza vaccine candidate, M-001, was fully enrolled. A total...
By David Bautz, PhD TSX:ATE.V READ THE FULL ATE.V RESEARCH REPORT Business Update Phase 2b Study Results in 1Q20 In March 2019, Antibe Therapeutics Inc. (TSX:ATE.V) announced that the Phase 2b dose-ranging, efficacy study of ATB-346 had commenced. It is a randomized, double blind, placebo controlled trial in approximately 360 patients suffering...
By John Vandermosten, CFA OTC:PMN.TO | OTC:ARFXF The Alzheimer’s Disease (AD) space has been on a wild ride over the last year with Biogen fishtailing like a Mustang on a wet Los Angeles freeway. During Phase II interim analysis Biogen’s AD drug BAN2401 initially appeared to be ineffective,...
By David Bautz, PhD NYSE:OGEN READ THE FULL OGEN RESEARCH REPORT Business Update Enrollment Complete for Phase 2 Trial of AGO13 in Oral Mucositis Oragenics, Inc. (NYSE:OGEN) is currently conducting a Phase 2 clinical trial of its lead development compound AG013 in the prevention of severe oral...
By David Bautz, PhD TSX:MDNA.TO | OTC:MDNAF READ THE FULL MDNA.TO RESEARCH REPORT Business Update Additional P2b Data for MDNA55 Presented On November 25, 2019, Medicenna Therapeutics Corp. (TSX:MDNA.TO) (OTC:MDNAF) announced the presentation of additional clinical data from the ongoing Phase 2b clinical trial of MDNA55, an IL-4 targeted toxin, in patients...
By John Vandermosten, CFA NASDAQ:HTBX READ THE FULL HTBX RESEARCH REPORT Heat Biologics, Inc. (NASDAQ:HTBX) reported third quarter 2019 results in a November 15 release following the submission of the companion 10-Q to the SEC the prior day. Since the beginning of the year, Heat has attended numerous scientific...
By John Vandermosten, CFA OTC:PMN.TO | OTC:ARFXF READ THE FULL PMN.TO RESEARCH REPORT During 2019 the environment for β-amyloid (βA) focused Alzheimer’s Disease (AD) drug development has been on a roller coaster. In March, Biogen announced that its Phase III trials for aducanumab failed to reach their endpoints and...
By John Vandermosten, CFA NASDAQ:AZRX READ THE FULL AZRX RESEARCH REPORT AzurRx BioPharma, Inc. (NASDAQ:AZRX) filed its 2019 third quarter 10-Q with the SEC for the three month period ending September 30, 2019. Highlights for the reporting period and to date include the announcement and first dosing in a...
By Brian Marckx, CFA NASDAQ:MYOS READ THE FULL MYOS RESEARCH REPORT Q3 2019 Update: Positive Clinical Data, Word-of-Mouth Driving Interest at Consumer and Professional Levels… MYOS Rens Technology (NASDAQ:MYOS) reported Q3’19 financial results and provided a business update. Relative to the financials, MYOS turned in perhaps their best performance and...
By David Bautz, PhD NASDAQ:INMB READ THE FULL INMB RESEARCH REPORT Business Update Link Between Obesity and Alzheimer’s Presented at Society for Neuroscience Annual Meeting On October 21, 2019, INmune Bio, Inc. (NASDAQ:INMB) announced a presentation at the Society for Neuroscience 49th Annual Meeting showing the company’s lead compound, XPro1595, appears to...